# A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

> **NCT06657768** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 128 (estimated)

## Conditions studied

- Alzheimer Disease
- Healthy

## Interventions

- **DRUG:** LY4006895
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06657768
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-29
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657768, "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06657768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*